Start / PharmaTalkRadio / Bispecific antibodies for pd 1 and vegf impact and market dynamics for io landscape

PharmaTalkRadio

Bispecific Antibodies for PD-1 and VEGF: Impact and Market Dynamics for IO Landscape

20 min • 23 april 2025

Summary:
This podcast, recorded at the 2025 Immuno-Oncology 360º (IO360º) Summit, explores the clinical and market implications of emerging data on bispecific antibodies targeting PD-1 and VEGF and their potential to disrupt existing immunotherapy paradigms.

More specifically:

Assessing the potential of this therapeutic approach to challenge established treatments like pembrolizumab by targeting both PD-1 and VEGF
Insights into how these developments could influence industry trends and investor sentiment
Forward-looking forecasts on market share and commercial positioning for PD-1/PD-L1 and VEGF-targeting therapies

In this podcast:

Roy Baynes, MD, PhD, EVP & CMO at Eikon Therapeutics

Asthika Goonewardene, MBA, Managing Director, Senior Biotech Analyst at Truist Securities

For more information, go to IO360summit.com

Senaste avsnitt

De-Risking Clinical Operations by Taking a Scaffolding Approach to Outsourcing

12 augusti | 28 min

Balancing Between Concentration and Volume when Developing Patient-Centric Biologics

12 augusti | 28 min

Directors' Talk DPHARM 2025 - AI Sessions; Part III

25 juli | 6 min

Innovations in Manufacturing to Make CAR-T More Accessible and Affordable

25 juli | 20 min

Achieving Oral Delivery of Peptides through Formulation and Molecule Design Approaches

25 juli | 29 min

Podcastbild

00:00 -00:00

Podcastbild

00:00 -00:00